Pfizer: Multiple Myeloma trials
The registry lists 44 Multiple Myeloma studies with Pfizer as lead sponsor. 6 are open to participants now and 14 have results posted.
Phase 1 17Phase 2 8Phase 3 6Phase 4 2No phase 12(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaNot yet recruitingNCT07927023
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsNot yet recruitingNCT07881835Phase 4
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingNCT06152575Phase 3
- Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingNCT06057402Phase 4
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Phase 3
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Phase 3
- A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USCompletedNCT06504524Results posted
- A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple MyelomaCompletedNCT05932290Results posted
- A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaCompletedNCT05565391Results posted
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Phase 2Results posted
- MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaTerminatedNCT05090566Phase 2Results posted
- A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to TreatmentCompletedNCT05014412Phase 2Results posted
- MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple MyelomaCompletedNCT04798586Phase 1Results posted
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbCompletedNCT04649359Phase 2Results posted
- A Safety Study of SEA-BCMA in Patients With Multiple MyelomaTerminatedNCT03582033Phase 1Results posted
- PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple MyelomaCompletedNCT03269136Phase 1Results posted
- A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsTerminatedNCT02663518Phase 1Results posted
- Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Phase 3Results posted
- CP-751,871 Treatment For Patients With Multiple MyelomaCompletedNCT01536145Phase 1Results posted
- An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2Results posted
- A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in TaiwanActive, not recruitingNCT07391761
- A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care TherapiesCompletedNCT06592222
- Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).Active, not recruitingNCT06581848
- Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.Active, not recruitingNCT06479954
- A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)Active, not recruitingNCT06215118Phase 1
- A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedNCT05896774Phase 1
- A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related DiseasesCompletedNCT05742217
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple MyelomaActive, not recruitingNCT05675449Phase 1
- A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic MalignanciesCompletedNCT05567887Phase 1
- Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple MyelomaNo longer availableNCT05462639
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantActive, not recruitingNCT05317416Phase 3
- Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)No longer availableNCT05238311
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
- A Safety Study of SGN-CD48A in Patients With Multiple MyelomaTerminatedNCT03379584Phase 1
- A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT02954796Phase 1
- A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)CompletedNCT02092922Phase 2
- A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple MyelomaCompletedNCT01989325Phase 2
- Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and OncologyCompletedNCT01626547
- A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01248923Phase 1
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00821249Phase 1/2
- Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT00525447Phase 1
- Study of SGN-40 in Patients With Refractory or Recurrent Multiple MyelomaCompletedNCT00079716Phase 1
- Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of ThrombocytopeniaCompletedNCT00037791Phase 3
- Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple MyelomaCompletedNCT00036140Phase 1